


Research use only. Not for use in diagnostic procedures.

<sup>125</sup>I Research Reagents

# [<sup>125</sup>I]-(-)lodocyanopindolol

## Product Number: NEX189



### LOT SPECIFIC INFORMATION:

		Package Size	Volume
		as of	
CALCULATED AS OF:	3-Mar-2025	11-Apr-2025	
		3.70 MBq	1.00 ml
LOT NUMBER:	CW41150	100 μCi	
		18.6 MBq	5.00 ml
SPECIFIC ACTIVITY:	81.4 TBq/mmol	500 μCi	
	2200 Ci/mmol		
	200 MBq/µg		
	5400 μCi/μg		
CONCENTRATION:	6.60 MBq/ml		
	178.3 µCi/ml		

**RADIOCHEMICAL PURITY:** ≥ 95%

≥ 95%

MOLECULAR WEIGHT: 4

Package Size Information

411.0

**PACKAGING:** [<sup>125</sup>I]-(-)lodocyanopindolol is in a solution containing 1-propanol:water:phenol (approximately 50:50:1.2). It is shipped on dry ice.

**SPECIAL INFORMATION:** This compound is light sensitive. Exposure to light may hasten decomposition. [<sup>125</sup>I]-(-)odocyanopindolol is supplied in a red NENSURE™vial which contains a U.V. inhibitor.

**STABILITY AND STORAGE:** [<sup>125</sup>]-(-)odocyanopindolol should be stored at 4°C or lower in the dark. Under these conditions the product is stable and usable for use in receptor binding studies for at least six weeks after fresh lot date.

**SPECIFIC ACTIVITY:** The initial specific activity of  $[^{125}I]$ -(-)lodocyanopindolol is 2200 Ci/mmol, (81 TBq/mmol), 5400  $\mu$ Ci/ $\mu$ g (200 MBq/ $\Box$ g). Preparative HPLC is used to separate unlabeled (-)cyanopindolol from  $[^{125}I]$ -(-)lodocyanopindolol. Upon decay,  $[^{125}I]$ -(-)lodocyanopindolol undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on  $^{125}I$  decay and decay catastrophe of  $^{125}I$  labeled

**RADIOCHEMICAL PURITY:** Initially greater than 95% radiochemically pure as determined by HPLC.

**PREPARATIVE PROCEDURE:** (-)Cyanopindolol is radioiodinated with no carrier added <sup>125</sup>I using a modification of the Hunter and Greenwood method<sup>6</sup> and is purified by reversed phase HPLC.

**INSTRUCTIONS FOR USE:** If necessary, remove the 1-propanol and water by evaporation. Small aliquots may be evaporated under a gentle stream of dry nitrogen or dry air. (A volatile radioiodine trap is supplied for use during evaporation of the solvent). Rotary evaporation at ambient temperature is recommended for larger volumes. Since [<sup>125</sup>I]-(-)lodocyanopindolol degrades more rapidly on evaporation generation of the solvent complete

evaporation.

- . /

**AVAILABILITY:** [<sup>125</sup>I]-(-)lodocyanopindolol is routinely available from stock and is prepared fresh and packaged for shipment on the first Monday of each month. Please inquire for larger package sizes.

**HAZARD WARNING:** This product contains a chemical (s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion and inhalation. It is corrosive and irritating to the eyes, skin and respiratory tract, is highly toxic and flammable. Target organs are the eyes, central nervous system, kidneys, liver and heart.

#### **RADIATION UNSHIELDED:** 280mR/ hr/mCi at vial surface. **REFERENCES:**

- 1. Doyle, V.M., Buhler, F.R., Burgisser, E., *Eur. J. Pharm.* <u>99</u> 353 (1984).
- 2. Schmidt, J., J. Biol. Chem. 259 1660 (1984).
- 3. Loring, R.H., Jones, S.W., Matthews-Bellinger, J., Salpeter, M.M., J. Biol. Chem. 257 1418 (1982).
- 4. Berridge, M.S., Jiang, V.W., Welch, M.J., Rad. Res. 82 467 (1980).
- 5. Charlton, D.E., Rad. Res. 107 163 (1986).
- 6. Hunter, W.M. and Greenwood, F.C., *Nature* <u>194</u>, 495 (1962).
- Engel, G., Hoyer, D., Berthold, R. and Wagner, H., Naunyn-Schmiedeberg's Arch. Pharmacol. <u>317</u> 227-285 (1985).
- 8. Engel, G., Triangle 19 69-75 (1980).
- 9. Hoyer, D., Engel, G., and Berthold, R., Naunyn-Schmiedeberg's Arch. Pharmacol. 318 319-329 (1982).

#### IUDINE-125 DECAY CHAKI HALF LIFE=00 days

Radiations: Gamma 35.5 keV (7%), X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16	18
0	1.000	.977	.955	.933	.912	.891	.871	.851	.831	.812
20	.794	.776	.758	.741	.724	.707	.691	.675	.660	.645
40	.630	.616	.602	.588	.574	.561	.548	.536	.524	.512
60	.500	.489	.477	.467	.456	.445	.435	.425	.416	.406
80	.397	.388	.379	.370	.362	.354	.345	.338	.330	.322
100	.315	.308	.301	.294	.287	.281	.274	.268	.262	.256
120	.250	.244	.239	.233	.228	.223	.218	.213	.208	.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.



Revvity, Inc. 940 Winter Street Waltham, MA 02451 USA (800) 762-4000 www.revvity.com

For a complete listing of our global offices, visit <u>www.revvity.com</u> Copyright ©2023, Revvity, Inc. All rights reserved.